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Abstract
Background: Biomarkers may help clinicians predict cardiovascular risk. We aimed to determine if the addition of endocrine,
metabolic, and obesity-associated biomarkers to conventional risk factors improves the prediction of cardiovascular and all-
cause mortality.
Methodology/Principal Findings: In a population-based cohort study (the Study of Health in Pomerania) of 3,967 subjects
(age 20–80 years) free of cardiovascular disease with a median follow-up of 10.0 years (38,638 person-years), we assessed
the predictive value of conventional cardiovascular risk factors and the biomarkers thyrotropin; testosterone (in men only);
insulin-like growth factor-1 (IGF-1); hemoglobin A1c (HbA1c); creatinine; high-sensitive C-reactive protein (hsCRP);
fibrinogen; urinary albumin-to-creatinine ratio; and waist-to-height ratio (WHtR) on cardiovascular and all-cause
death. During follow-up, we observed 339 all-cause including 103 cardiovascular deaths. In Cox regression models with
conventional risk factors, the following biomarkers were retained as significant predictors of cardiovascular death after
backward elimination: HbA1c, IGF-1, and hsCRP. IGF-1 and hsCRP were retained as significant predictors of all-cause
death. For cardiovascular death, adding these biomarkers to the conventional risk factors changed the C-statistic from
0.898 to 0.910 (p=0.02). The net reclassification improvement was 10.6%. For all-cause death, the C-statistic changed from
0.849 to 0.853 (P=0.09).
Conclusions/Significance: HbA1c, IGF-1, and hsCRP predict cardiovascular death independently of conventional
cardiovascular risk factors. These easily assessed endocrine and metabolic biomarkers might improve the ability to predict
cardiovascular death.
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Introduction
Scoring systems based on classic risk factors, including sex, age,
hypertension, dyslipidemia, and smoking, predict the future risk of
cardiovascular events or death [1–5]; however, these risk factors
explain only part of cardiovascular risk.
Thus, attempts have been made to improve the prediction of
cardiovascular risk by adding multiple novel biomarkers to the
classic risk factors. These biomarkers have included markers of
inflammation, kidney function, cardiac damage, endothelial
function, metabolism, and oxidative stress, among others [6–11].
However, these novel markers’ abilities to improve prediction
were mostly disappointing. Many studies failed to detect a
clinically relevant improvement in risk prediction [7,8,10].
Biomarkers that appeared to improve prediction in some studies
[6,11] did not perform well in other cohorts [7].
Differences in hormone levels are associated with cardiovascular
risk. Both elevated and suppressed thyrotropin concentrations
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though not consistently [12]. Low levels of insulin-like growth
factor-1 (IGF-1), a metabolic and anabolic hormone as well as a
mediator of growth hormone action, have been associated with
increased cardiovascular mortality in some studies [13,14], but not
in all [15]. In men, low testosterone levels predict cardiovascular
and all-cause mortality [16–18]. Hemoglobin A1c (HbA1c)
predicted cardiovascular events in several studies, independently
of diabetes [19–21], although these results were not confirmed by
another study [22].
In addition, recent studies suggest that measures of abdominal
obesity, such as the waist-to-height ratio (WHtR), are associated
with cardiovascular risk, independent of classic cardiovascular risk
factors [23,24]. To our knowledge, no one has studied whether a
multimarker approach that includes endocrine and metabolic
parameters along with abdominal obesity will improve the
predictive value of classic cardiovascular risk factors.
We hypothesized that a comprehensive set of easily assessed
biomarkers that reflect different potential pathways of cardiovas-
cular risk, including hormonal imbalance, glucose metabolism,
abdominal obesity, inflammation, and kidney damage, adds
incrementally to the use of conventional risk factors to predict
cardiovascular and all-cause death.
Materials and Methods
Subjects
The Study of Health in Pomerania (SHIP) is a longitudinal,
representative, population-based cohort study in West Pomerania,
a region in northeast Germany. Baseline data was collected from
1997 through 2001. A total of 4,308 subjects (response proportion:
69%) participated [25,26]. All participants gave written informed
consent. The study conformed to the principles of the Declaration
of Helsinki, and was approved by the Ethics Committee of the
University of Greifswald.
Of the 4,308 participants, 18 pregnant women, 63 with
incomplete conventional cardiovascular risk factor information
and 260 with history of major cardiovascular events (stroke,
myocardial infarction or heart surgery) at baseline were excluded,
resulting in a study population of 3,967 subjects. Vital status
information was acquired at annual intervals from the time of
enrollment through December 2009. Subjects were censored at
either death or failure to follow-up. The median duration of
follow-up was 10.0 years (25
th percentile 9.3; 75
th percentile 10.0).
Death certificates were coded by a certified nosologist according to
the International Classification of Diseases, 10th revision (ICD10).
Additionally, two internists (H.W. and M.D.) independently
validated the underlying causes of death and performed a joint
reading together with a third internist (H.V.) in cases of
disagreement. Cardiovascular death included Codes I10 to I79.
Clinical assessments
Information on age, sex, and medical history was collected with
computer-aided personal interviews. Smoking status was assessed
by self-report, and subjects were categorized as either current
smokers (at least one cigarette per day within the past year) or non-
smokers. Anthropometric characteristics were measured according
to written, standardized instructions in accordance with World
Health Organization standards (WHO 1987). Waist circumference
was measured to the nearest 0.1 cm midway between the lower rib
margin and the iliac crest in the horizontal plane, using an inelastic
tape measure. Blood pressure was measured three times with an
appropriate-sized cuff after five minutes of rest in a sitting position,
and the mean of the second and third measurement was recorded.
The definition of diabetes mellitus was based on self-reported
physician’s diagnosis or self-reported use of antidiabetic medica-
tion in the last seven days. The history of cardiovascular disease
(CVD) was based on a self-reported history of myocardial
infarction, stroke or cardiac surgery.
Laboratory measurements
Non-fasting blood samples were drawn from the cubital vein,
with the patient in the supine position. A urine sample was
collected. The samples were taken between 07:00 a.m. and 04:00
p.m. and analyzed immediately or stored at 280uC until
biomarkers could be measured. In addition, internal quality
controls were performed at least daily.
Urine samples were stored for a maximum of 2 days until
measurement. Serum creatinine levels were determined with the
Jaffe ´ method (Hitachi 717; Roche Diagnostics, Germany). The
urinary albumin concentration was determined with a Behring
Nephelometer (Siemens BN albumin; Siemens Healthcare, Mar-
burg, Germany). Total and high-density lipoprotein (HDL)
cholesterol were measured photometrically (Hitachi 704; Roche,
Mannheim, Germany).
Serum IGF-1 was determined with automated two-site
chemiluminescence immunoassays (Nichols Advantage; Nichols
Institute Diagnostica GmbH, Bad Vilbel, Germany). Total
testosterone levels were measured with competitive chemilumi-
nescent enzyme immunoassays on an Immulite 2500 analyzer
(Siemens Immulite 2500 Total Testosterone, ref. L5KTW, Lot
110; Siemens Healthcare Medical Diagnostics, Bad Nauheim,
Germany). Serum thyrotropin levels were measured with im-
munochemiluminescence (Byk Sangtec Diagnostica GmbH,
Frankfurt, Germany). HbA1c levels were determined with high-
performance liquid chromatography (Bio-Rad Diamat, Munich,
Germany). Plasma fibrinogen concentrations were assayed as
described by Clauss (19), using an Electra 1600 analyzer
(Instrumentation Laboratory, Barcelona, Spain). HsCRP was
determined immunologically on a Behring Nephelometer II with
commercially available reagents from Dade Behring (Dade
Behring, Eschborn, Germany).
Statistical analyses
Categorical data were expressed as percentages; continuous
data were expressed as medians (25
th percentile; 75
th percentile).
Continuous variables were truncated at the 1
st and 99
th percentile.
Univariate analysis was performed, with x
2 testing for categorical
variables and Mann–Whitney U-tests for continuous distributions.
For regression analyses, skewed variables were log-transformed.
We included the following parameters as conventional risk
factors: age (continuous); sex (binary); systolic blood pressure
(continuous); antihypertensive medication (binary); HDL choles-
terol (continuous); total cholesterol (continuous); diabetes (binary);
and current smoking (binary). We assessed the following
biomarkers as continuous variables, analyzing the effects of an
increase of one standard deviation (SD) from the mean:
thyrotropin, IGF-1, testosterone, hsCRP, fibrinogen, HbA1c,
creatinine, urinary albumine-to-creatinine ratio (UACR), and
WHtR. Additionally, we analyzed cutoffs that were considered
clinically useful and were derived from the literature for the
following variables: thyrotropin below and above the reference
range versus the reference range (0.25–2.12 mIU/l) [27]; IGF-1
below the 10
th sex- and age-specific percentile [14]; and
testosterone below 10.4 nmol/l [16]. Testosterone was measured
in men only, and all analyses that included testosterone were
performed in men only.
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cardiovascular death. First, we performed Cox proportional
hazards regression analyses for single biomarkers, unadjusted
and adjusted for conventional risk factors, to predict cardiovascu-
lar death. Second, we included all biomarkers that were significant
after adjustment into a prediction model, using backward
elimination with conventional risk factors forced into the model.
Third, we used the C-statistic, as described by Pencina et al. [28],
to compare the predictive values of conventional risk factors with
single, novel risk factors and the models built in the second step
Table 1. Baseline characteristics.
Characteristics N (m/w) Men Women
Age, years 1892/2075 50 (36; 63) 48 (35; 61)
Current Smokers, % 1892/2075 38.2 28.6
Diabetes, % 1892/2075 7.7 6.7
Antihypertensive medication, % 1892/2075 26.3 26.7
Systolic blood pressure, mm Hg 1892/2075 141 (129; 153) 126 (114; 142)
Total cholesterol, mg/dl 1892/2075 222 (193; 251) 218 (189; 251)
HDL cholesterol, md/dl 1892/2075 48 (41; 58) 60 (50; 71)
Biomarkers
Waist-to-height ratio 1892/2075 0.54 (0.50; 0.59) 0.50 (0.44; 0.57)
HbA1c, % 1888/2066 5.4 (5.0; 5.8) 5.2 (4.8; 5.6)
IGF-1, ng/ml 1784/1971 133 (104; 170) 135 (102; 174)
Testosterone, nmol/l 1812/0 16.0 (12.7; 20.3) -
Thyrotropin, mU/l 1872/2046 0.65 (0.43; 0.94) 0.68 (0.44; 1.02)
High-sensitive CRP, mg/l 1745/1917 1.25 (0.65; 2.82) 1.49 (0.68; 3.57)
Fibrinogen, g/l 1887/2067 2.80 (2.43; 3.30) 2.90 (2.54; 3.40)
Serum creatinine, mmol/l 1884/2073 90 (83; 98) 77 (71; 83)
Urinary Albumin-to-Creatinine Ratio, mg/g 1735/1753 7.1 (4.3; 15.0) 9.3 (5.8; 17.3)
N(m/w) = number of men and women with data on the respective parameter; HDL = high-density lipoprotein; HbA1c = hemoglobin A1c; IGF-1 = Insulin-like growth
factor 1; CRP = C-reactive protein. Continuous data are expressed as median (25th; 75th percentile); nominal data are given as percentages.
doi:10.1371/journal.pone.0033084.t001
Table 2. Prediction of cardiovascular death by single biomarkers.
Trans-formation SD Total Events Unadjusted HR (95%CI) p Adjusted HR (95%CI)* p
WHtR, 1-SD increase - 0.08 3967 103 2.31 (1.95; 2.75) ,.001 1.41 (1.13; 1.78) 0.003
HbA1c, 1-SD increase - 0.90% 3954 102 1.64 (1.51; 1.78) ,.001 1.34 (1.13; 1.58) 0.001
IGF-1 57.6 ng/ml 3755 96
,10th percentile - 2.32 (1.41; 3.84) 0.001 2.43 (1.46; 4.05) 0.001
1-SD increase - 0.37 (0.28; 0.50) ,.001 0.76 (0.56; 1.04) 0.09
Testosterone 6.01 nmol/l 1812 58
,10.4 nmol/l - 3.47 (1.99; 6.06) ,.001 1.90 (1.05; 3.47) 0.04
1-SD increase - 0.64 (0.48; 0.86) 0.003 0.89 (0.68; 1.15) 0.37
Thyrotropin 0.77 mU/l 3918 101
1-SD increase log 0.81 (0.68; 0.967) 0.02 1.03 (0.86; 1.22) 0.78
,0.25 mU/l (ref.: 0.25–2.12) - 1.92 (1.11; 3.32) 0.02 1.00 (0.57; 1.75) 1.00
.2.12 mU/l (ref.: 0.25–2.12) - no events - no events -
hsCRP, 1-SD increase log 1.10 mg/l 3662 91 2.07 (1.71; 2.51) ,.001 1.60 (1.29; 1.98) ,.001
Fibrinogen, 1-SD increase log 0.22 g/l 3954 102 1.82 (1.52; 2.19) ,.001 1.21 (0.98; 1.48) 0.07
Serum creatinine, 1-SD increase log 0.17 mmol/l 3957 102 1.49 (1.34; 1.66) ,.001 1.11 (0.93; 1.33) 0.27
UACR, 1-SD increase log 1.06 mg/g 3488 96 1.72 (1.48; 1.99) ,.001 1.09 (0.91; 1.30) 0.36
SD = standard deviation; HR = hazard ratio; CI = confidence interval; WHtR = waist-to-height-ratio; HbA1c = hemoglobin A1c; IGF-1 = Insulin-like growth factor 1;
hsCRP = high-sensitive C-reactive protein; UACR = urinary albumin-to-creatinine ratio.
*Models were adjusted for age, sex, systolic blood pressure, high-density lipoprotein cholesterol, total cholesterol, antihypertensive medication, diabetes, and current
smoking.
doi:10.1371/journal.pone.0033084.t002
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moderate (2% to 9%) and high (.9%) risk, based on the
recommendations of the European Society of Cardiology [4], and
calculated the net reclassification improvement (NRI) for cardio-
vascular death. The bias-corrected accelerated bootstrap resam-
pling procedure of Efron and Tibshirani was used to obtain 95%
confidence intervals for NRIs. Observed risk at 10-years estimated
from Kaplan-Meier curve were used to estimate the expected
number of subjects who died and who did not die at 10-year
follow-up.
In secondary analyses, we repeated the first three steps with all-
cause death as outcome. A two-sided p-value of ,0.05 was
considered statistically significant. Statistical analyses were per-
formed with SAS 9.1 (SAS Institute Inc., Cary, NC, USA).
Results
Study sample
Baseline characteristics are shown in table 1. During the 38,638
person-years of follow-up, we observed 339 (8.6%) all-cause deaths
(rate per 1,000 person years: 8.8), including 103 (2.6%) deaths due
to cardiovascular disease (rate per 1,000 person years: 2.7).
Prediction of events by single biomarkers
The results of the Cox regression analyses for predicting
cardiovascular death with single biomarkers are shown in table 2.
WHtR, HBA1c, testosterone below 10.4 nmol/l, hsCRP, and
IGF-1 levels below the 10
th sex- and age-specific percentile
remained significant predictors after adjustment for conventional
risk factors.
For all-cause death, WHtR, hsCRP, fibrinogen, IGF-1 levels
below the 10
th percentile, and testosterone below 10.4 nmol/l
remained significant predictors after adjustment for conventional
risk factors (table 3).
Risk prediction with combined biomarkers and risk
factors
Table 4 shows the results of backward elimination models that
included all significant biomarkers from the previous step with
conventional risk factors forced into the model for cardiovascular
Table 3. Prediction of all-cause death by single biomarkers.
Trans-formation SD Total Events Unadjusted HR (95%CI) p Adjusted HR (95%CI)* p
WHtR, 1-SD increase - 0.08 3967 339 1.92 (1.74; 2.12) ,.001 1.19 (1.05; 1.36) 0.008
HbA1c, 1-SD increase - 0.90% 3954 338 1.44 (1.36; 1.53) ,.001 1.09 (0.98; 1.22) 0.11
IGF-1 57.6 ng/ml 3755 319
,10th percentile - 1.47 (1.07; 2.02) 0.02 1.60 (1.16; 2.20) 0.004
1-SD increase - 0.47 (0.40; 0.55) ,.001 0.87 (0.75; 1.03) 0.10
Testosterone 6.01 nmol/l 1812 204
,10.4 nmol/l - 2.24 (1.61; 3.11) ,.001 1.53 (1.08; 2.16) 0.02
1-SD increase - 0.85 (0.73; 0.98) 0.03 1.01 (0.88; 1.15) 0.94
Thyrotropin 0.77 mU/l 3918 331
1-SD increase log 0.85 (0.77; 0.94) 0.002 1.06 (0.96; 1.17) 0.24
,0.25 mU/l (ref.: 0.25–2.12) - 1.65 (1.20; 2.29) 0.002 0.94 (0.68; 1.31) 0.71
.2.12 mU/l (ref.: 0.25–2.12) - 1.01 (0.54; 1.90) 0.98 1.06 (0.56; 2.02) 0.85
hsCRP, 1-SD increase log 1.10 mg/l 3662 315 1.65 (1.49; 1.83) ,.001 1.30 (1.16; 1.46) ,.001
Fibrinogen, 1-SD increase log 0.22 g/l 3954 337 1.65 (1.49; 1.82) ,.001 1.16 (1.04; 1.30) 0.008
Serum creatinine, 1-SD increase log 0.17 mmol/l 3957 337 1.41 (1.32; 1.51) ,.001 1.08 (0.97; 1.20) 0.14
UACR, 1-SD increase log 1.06 mg/g 3488 318 1.51 (1.39; 1.65) ,.001 1.07 (0.97; 1.19) 0.18
SD = standard deviation; HR = hazard ratio; CI = confidence interval; WHtR = waist-to-height-ratio; HbA1c = hemoglobin A1c; IGF-1 = Insulin-like growth factor 1;
hsCRP = high-sensitive C-reactive protein; UACR = urinary albumin-to-creatinine ratio.
*Models were adjusted for age, sex, systolic blood pressure, high-density lipoprotein cholesterol, total cholesterol, antihypertensive medication, diabetes, and current
smoking.
doi:10.1371/journal.pone.0033084.t003
Table 4. Prediction of cardiovascular death by backward-
elimination.
HR (95%CI)* p
Conventional cardiovascular risk factors
age, per year 1.13 (1.10; 1.16) ,.001
Smoker 1.92 (1.13; 3.28) 0.02
Antihypertensive medication 1.15 (0.72; 1.83) 0.56
HDL cholesterol, 1-SD increase 0.77 (0.58; 1.01) 0.06
Female 0.67 (0.42; 1.07) 0.10
Diabetes 1.50 (0.83; 2.71) 0.18
Systolic BP, 1-SD increase 1.18 (0.95; 1.47) 0.13
Total cholesterol, 1-SD increase 0.95 (0.74; 1.20) 0.66
Biomarkers
HbA1c, 1-SD increase 1.28 (1.07; 1.51) 0.005
hsCRP, 1-SD increase 1.50 (1.21; 1.87) ,.001
IGF-1 ,10th percentile 2.18 (1.30; 3.67) 0.003
BP = blood pressure; SD = standard deviation; HR = hazard ratio; CI =
confidence interval; WHtR = waist-to-height-ratio; HbA1c = hemoglobin A1c;
IGF-1 = Insulin-like growth factor 1; hsCRP = high-sensitive C-reactive protein;
UACR = urinary albumin-to-creatinine ratio; Cox regression analysis with
backward elimination with a p-value of 0.05.
*Conventional cardiovascular risk factors were forced into the model.
doi:10.1371/journal.pone.0033084.t004
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predictors after backward elimination. In men, low testosterone was
not retained in the model after backward elimination. Therefore, we
did not continue with separate analyses by sex.HsCRP and low IGF-
1 remained significant predictors for all-cause death (table 5).
Table 6 shows the C-statistics for cardiovascular death. Adding
biomarkers to all conventional risk factors lead to a significant (p =
0.02) but slight change in the C-statistic for cardiovascular death from
0.898 (95%-CI 0.873–0.923) to 0.910 (95%-CI 0.886–0.934). For all-
cause death, the C-statistic changed (p = 0.09) from 0.849 (95%-CI
0.830–0.868) to 0.853 (95%-CI 0.833–0.872) after biomarkers were
included (table 7). The reclassification for cardiovascular death was
10.61% (95%-CI 20.28–24.86) as shown in table 8.
Discussion
In this population-based cohort study, we analyzed whether
combining endocrine and metabolic parameters with a marker of
abdominal obesity improved the prediction of cardiovascular
death with conventional risk factors. We identified a set of
additional biomarkers, including low IGF-1, HbA1c, and hsCRP
that caused a moderate but significant improvement in the
prediction of cardiovascular deaths and correctly reclassified 11%
of the population at risk. The predictive value was stronger for
cardiovascular than for all-cause death. This result is not surprising
because the risk factors selected were aimed at cardiovascular risk
and not at other causes of death.
Our results confirm the findings of previous studies showing that
hsCRP is a significant predictor of cardiovascular risk in a
multimarker approach [7–11]. Our results extend the findings of
previous reports by assessing the associations of HbA1c, and low
IGF-1 in this context.
HbA1c was included in one multimarker study, but only in
subjects with diabetes [9]. Several studies focusing on HbA1c
found a predictive role independent of diabetes [19–219]. We
confirmed this role in combination with other biomarkers.
Testosterone in men and thyrotropin did not improve
prediction. Although low levels of testosterone have been shown
to predict mortality even after adjustment for cardiovascular risk
factors [18], the fact that the associations became weaker after
adjustment in our study suggests that the effects of testosterone are
mediated by cardiovascular risk factors. This result is consistent
with previous studies showing that testosterone is associated with
cardiovascular risk factors [30,31]. Similar associations may play a
role in the results found for thyrotropin [32].
Low IGF-1 was a significant predictor. Experimental data show
IGF-1’s protective effects against systemic inflammation, insulin
resistance, and free fatty acid production, all of which are
consequences of obesity [33]. IGF-1 remained a significant
predictor among parameters that reflect these different pathways.
This finding suggests that additional parameters are involved in
the association between IGF-1 and cardiovascular death. Possibly,
the effects of IGF-1 on endothelial function and cardiac growth
and function [34,35] or other, unknown factors play a part.
Previous studies have shown that WHtR is a strong and linear
predictor of cardiovascular risk, compared with other measures of
abdominal and overall obesity [23,24,36] whereas BMI shows a
U-shaped association with cardiovascular risk and mortality [37–
39]. WHtR was not significant in this multimarker approach. Most
likely, this is due to the fact that abdominal obesity, as measured
by the WHtR, increases risk by promoting conventional
cardiovascular risk factors.
Table 5. Prediction of all-cause death by backward-
elimination.
HR (95%CI)* p
Conventional cardiovascular risk factors
age, per year 1.10 (1.09; 1.11) ,.001
Smoker 2.17 (1.66; 2.84) ,.001
Antihypertensive medication 1.20 (0.93; 1.54) 0.16
HDL cholesterol, 1-SD increase 0.99 (0.87; 1.12) 0.86
Female 0.51 (0.39; 0.65) ,.001
Diabetes 1.79 (1.34; 2.38) ,.001
Systolic BP, 1-SD increase 1.03 (0.91; 1.16) 0.66
Total cholesterol, 1-SD increase 1.11 (0.98; 1.25) 0.09
Biomarkers
hsCRP, 1-SD increase 1.29 (1.15; 1.45) ,.001
IGF-1 ,10th percentile 1.49 (1.08; 2.07) 0.02
BP = blood pressure; SD = standard deviation; HR = hazard ratio; CI =
confidence interval; WHtR = waist-to-height-ratio; HbA1c = hemoglobin A1c;
IGF-1 = Insulin-like growth factor 1; hsCRP = high-sensitive C-reactive protein;
UACR = urinary albumin-to-creatinine ratio; Cox regression analysis with
backward elimination with a p-value of 0.05.
*Conventional cardiovascular risk factors were forced into the model.
doi:10.1371/journal.pone.0033084.t005
Table 6. Improvement of prediction of cardiovascular death by biomarkers.
C-statistic*of cardiovascular deaths with 95% CI
(3602 subjects, 91 events)
Net reclassification improvement with
95% CI
{ (%)
Conventional cardiovascular risk factors only 0.898 (0.873; 0.923)
Biomarkers
HbA1c, 1-SD increase 0.902 (0.877; 0.927 4.52 (23.25; 17.39)
hsCRP, 1-SD increase 0.906 (0.881; 0.930) 4.71 (22.70; 15.92)
IGF-1 ,10th percentile 0.902 (0.877; 0.927) 5.80 (20.66; 21.81)
All biomarkers 0.910 (0.886; 0.934) 10.61 (20.28; 24.86)
CI = confidence interval; SD = standard deviation; WHtR = waist-to-height-ratio; HbA1c = hemoglobin A1c; IGF-1 = Insulin-like growth factor 1; hsCRP = high-
sensitive C-reactive protein. Conventional cardiovascular risk factors include age, sex, systolic blood pressure, high-density lipoprotein cholesterol, total cholesterol,
antihypertensive medication, diabetes, and current smoking.
*For conventional risk factors only or conventional risk factors + biomarkers.
{The bias-corrected accelerated bootstrap resampling procedure was used to calculate 95% confidence intervals.
doi:10.1371/journal.pone.0033084.t006
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predict cardiovascular risk has been a focus of interest in recent
years. Our results show a modest improvement in prediction
compared with other studies [7–10]. The inclusion of IGF-1 and
HbA1c may have contributed to this effect. Other studies found
higher incremental effects of biomarkers than our study [6,11].
Selection of high-risk patients or different outcomes might play a
part in these findings.
It has been shown that biomarkers can result in relevant
reclassification, even in the absence of significant increases in C-
statistics [9]. In our study, 11% of subjects were correctly net
reclassified by the new biomarkers. Generally, one can expect that
the lower the costs for a biomarker are the greater is the
willingness to accept small increments in discrimination.
We selected biomarkers that can be easily obtained in every-day
clinical practice. Therefore, the increment in our study, though
only moderate, might be relevant if validated, given the low cost
and effort associated with biomarker assessment – HbA1c is a
routine laboratory parameter and hsCRP is increasingly used in
risk assessment. IGF-1 is mainly used as marker of pathological
changes in growth hormone secretion in an endocrine setting. All
of the biomarkers we measured can be assessed clinically or in
blood and do not require fasting.
Several limitations need to be addressed. First, because we
aimed to explore new biomarkers, our findings need validation in
additional cohorts. We did not test other potentially relevant
markers, such as troponin or B-type natriuretic peptide. We expect
that these factors are more relevant in populations with higher
baseline risks of cardiac damage than our sample had. As in any
study of risk prediction, multiple testing is an issue, although we
Table 7. Improvement of prediction of all-cause death by
biomarkers.
C-statistic*of all-cause
death with 95% CI
(3602 subjects, 311 events)
Conventional cardiovascular risk factors only 0.849 (0.830; 0.868)
Biomarkers
hsCRP, 1-SD increase 0.852 (0.833; 0.871)
IGF-1 ,10th percentile 0.850 (0.830; 0.869)
All biomarkers 0.853 (0.833; 0.872)
CI = confidence interval; SD = standard deviation; WHtR = waist-to-height-
ratio; HbA1c = hemoglobin A1c; IGF-1 = Insulin-like growth factor 1; hsCRP =
high-sensitive C-reactive protein. Conventional risk factors include age, sex,
systolic blood pressure, high-density lipoprotein cholesterol, total cholesterol,
antihypertensive medication, diabetes, and current smoking.
*For conventional cardiovascular risk factors only or conventional
cardiovascular risk factors + biomarkers.
doi:10.1371/journal.pone.0033084.t007
Table 8. Reclassification of cardiovascular deaths using the model with both conventional cardiovascular risk factors and
biomarkers retained after backward-elimination.
Model with conventional risk
factors + biomarkers
Reclassified into
new category, %
Model with conventional
risk factors only ,2% 2; 9% .9% Total, n Lower Higher
,2%
Subjects included 2631 58 4 2693 0.0 2.2
Subjects who died of CVD* 25 6 0 31 0.0 19.4
Subjects who did not die of CVD 2606 52 0 2658 0.0 2.0
Observed risk, %
{ 0.93 10.73 0
2%; 9%
Subjects included 153 434 58 645 23.7 9.0
Subjects who died of CVD* 4 25 9 38 10.5 23.7
Subjects who did not die of CVD 149 409 49 607 24.5 8.1
Observed risk, %
{ 2.56 5.80 16.00
.9%
Subjects included 0 75 189 264 28.4 0.0
Subjects who died of CVD* 0 4 25 29 13.8 0.0
Subjects who did not die of CVD 0 71 164 235 30.2 0.0
Observed risk, %
{ 0 5.79 13.15
Total
Subjects included 2784 567 251 3602
Subjects who died of CVD* 28 36 35 99 NRI = 10.61%
Subjects who did not die of CVD 2756 531 216 3503
Observed risk, %
{ 1.02 6.34 13.80
CVD = cardiovascular disease; NRI = net reclassification improvement. Conventional cardiovascular risk factors include age, sex, systolic blood pressure, high-density
lipoprotein cholesterol, total cholesterol, body-mass-index, antihypertensive medication, lipid-lowering medication, diabetes, and current smoking.
*10-year Kaplan-Meier estimates were used to estimate the number of subjects who died and who did not die.
{Observed risk at 10-years was estimated from the Kaplan-Meier curve.
doi:10.1371/journal.pone.0033084.t008
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addition, we only assessed cardiovascular and all-cause mortality.
We do not know if our findings are generalizable to other
cardiovascular events.
In summary, we found a set of biomarkers that improve the
prediction of cardiovascular death. The effort required to assess
these parameters is low. Thus, the increase in the C-statistic,
though only moderate, and the net reclassification of 11% could
have a clinical benefit, once validated.
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